Uncategorized
Exscientia, AI Biotech Firm, Announces Workforce Reduction Amidst Pipeline Changes and CEO Departure
Exscientia, AI biotech, workforce reduction, pipeline cut, CEO firing, restructuring, pharmaceutical industry, drug discovery
AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030
AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.
Revolutionizing Drug Discovery: Sanofi, OpenAI, and Formation Bio Join Forces
Sanofi, OpenAI, Formation Bio, AI, drug development, partnership, drug discovery, pharmaceuticals, artificial intelligence, healthcare innovation.
AltruBio Secures $225M for Midphase Ulcerative Colitis Program Following Checkpoint Drug Modification
AltruBio, checkpoint drug, ulcerative colitis, $225M funding, midphase program, biotechnology, drug development, healthcare innovation.
AstraZeneca Targets $80 Billion in Revenue by 2030: A Rapid Growth Trajectory
AstraZeneca, revenue target, 2030, growth trajectory, pharmaceutical industry, drug development, healthcare solutions.
Tezspire Clinical Trials by AstraZeneca and Amgen: Empowering Patient Choice in COPD Treatment
Tezspire, AstraZeneca, Amgen, clinical trials, COPD, patient choice, pivotal studies, treatment.
Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment
Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.
Extended Data from Gilead’s PBC Program Strengthens Case Ahead of FDA Ruling
Gilead, PBC Program, FDA Decision, Long-term Data, Primary Biliary Cholangitis
Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment
J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.
EU Upholds Approval of PTC Therapeutics’ Duchenne Muscular Dystrophy Treatment
EU, PTC Therapeutics, Duchenne Muscular Dystrophy (DMD), treatment, approval, rejection, committee.